3rd Party Biotechnology Industry News

Crossbow Therapeutics has successfully hit a $77 million series B [...]

Since raising a mind-boggling $1 billion in 2024, AI-driven Xaira [...]

The pharma is transitioning operations and management of its New [...]

Bicycle Therapeutics is letting more air out of its operations, [...]

Swiss pharma Roche is staying in lockstep with Eli Lilly, [...]

Astellas is pulling out of its $1.6 billion biobucks partnership [...]

Structure Therapeutics has touted the 16% weight loss seen by [...]

In a 14-month follow-up, Sana Biotechnology has found that its [...]

Inovio Pharmaceuticals has laid off staff and prioritized programs to [...]

Immutep and the Australian biotech’s investors have been caught off [...]